Efficacy and safety of sodium zirconium cyclosilicate in patients with baseline serum potassium level ≥ 5.5 mmol/L: pooled analysis from two phase 3 trials
Abstract Background Reliable, timely-onset, oral treatments with an acceptable safety profile for patients with hyperkalemia are needed. We examined the efficacy and safety of sodium zirconium cyclosilicate (SZC; formerly ZS-9) treatment for ≤ 48 h in patients with baseline serum potassium level ≥ 5...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2019-12-01
|
Series: | BMC Nephrology |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12882-019-1611-8 |